Connetics Launches AcneMedicine.com; A New Online Resource to Help Acne Sufferers Take Control of Their Acne.

PALO ALTO, Calif. -- Connetics Corporation (NASDAQ:CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products, announced today the launch of AcneMedicine.com (www.AcneMedicine.com), a new website designed to increase awareness of the causes and types of acne, to dispel common acne myths and to help acne sufferers know when to seek help from a dermatologist.

"Whether it is mild or severe, chronic or acute, acne can be embarrassing and distressing for teens and adults," states Jeanine Downey, MD, Director of Image Dermatology in Montclair, NJ, co-author of the book Beautiful Skin of Color, and a widely quoted skin expert in consumer magazines and guest on national television shows. "AcneMedicine.com will educate acne sufferers on alternative treatment options and encourage patients to see their doctors rather than rely on over-the-counter products that promise clear skin, but often do not deliver on the promise."

Acne, the most common skin disease, affects more than 17 million people in the U.S., with 90 percent of those afflicted being between the ages of 12 and 35. The topical prescription acne market in the U.S. is valued at $1.3 billion with approximately 17 million prescriptions written annually.

AcneMedicine.com provides easy-to-read and highly informative sections, including an About Acne section that features categories such as Acne Causes, Teen Acne, Adult Acne, Body Acne, Acne Scars and Acne Scar Removal. Reading these sections will enable visitors to distinguish between acne facts and fiction and to know when to seek help and treatment.

For example, in the Body Acne section it states that 50 percent of acne sufferers have pimples on their chest, back and shoulders and that tight fitting clothes, backpacks or purse straps can aggravate body acne. This section stresses the importance of having an easy to apply acne product for treating hard to reach areas of the body.

"We recognize that many people are frustrated and very confused about their acne and their treatment options. Our goal with AcneMedicine.com is to help acne sufferers learn about the different types of acne they have and to get the help they need sooner rather than later," states Lincoln Krochmal, MD, Executive Vice President of Research and Product Development for Connetics Corporation. "As a leader in medical dermatology, we are delighted to bring a full complement of accurate information about acne to those who need it most."

About Connetics

Connetics Corporation is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market. Connetics has branded its proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) capsules and Evoclin(TM) (clindamycin) Foam, 1%. Connetics is developing Velac(R) (a combination of 1% clindamycin and 0.025% tretinoin) Gel, for treating acne, Desilux(TM) (desonide) VersaFoam-EF, 0.05%, a low-potency topical steroid formulated to treat atopic dermatitis, Primolux(TM) (clobetasol propionate) VersaFoam-EF, 0.05%, a super high-potency topical steroid formulation to treat atopic dermatitis and plaque psoriasis and Extina(R), a foam formulation of the antifungal drug ketoconazole. Connetics' product formulations aim to improve the management of dermatological diseases and provide significant product differentiation. In Connetics' marketed products, these formulations have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance. For more information about Connetics and its products, please visit www.connetics.com.

Forward-Looking Statements

Except for historical information, this press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act. All statements included in this press release that address activities, events or developments that Connetics expects, believes or anticipates will or may occur in the future, including, particularly, statements about the impact of and benefit offered by AcneMedicine.com, are forward-looking statements. These forward-looking statements are based on certain assumptions made by Connetics' management based on its experience and perception of the acne market and treatment options available for acne, historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond Connetics' control, and which could cause actual results or events to differ materially from those expressed in such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, risks and other factors that are discussed in documents filed by Connetics with the Securities and Exchange Commission from time to time, including Connetics' Annual Report on Form 10-K for the year ended December 31, 2004 and Form 10-Q for the quarter ended June 30, 2005. Forward-looking statements represent the judgment of the Company's management as of the date of this release, and Connetics disclaims any intent or obligation to update any forward-looking statements.

Press Release Code: (CNCT-G)